Davita Inc (DVA) Receives $79.00 Average Price Target from Brokerages

Shares of Davita Inc (NYSE:DVA) have been assigned a consensus rating of “Hold” from the fourteen ratings firms that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation, four have issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $79.00.

A number of equities research analysts recently commented on DVA shares. SunTrust Banks set a $75.00 target price on Davita and gave the company a “hold” rating in a research report on Thursday, December 21st. Zacks Investment Research upgraded Davita from a “strong sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. Bank of America upgraded Davita from a “neutral” rating to a “buy” rating and upped their target price for the company from $75.00 to $85.00 in a research report on Thursday, January 4th. TheStreet upgraded Davita from a “c” rating to a “b-” rating in a research report on Thursday, January 4th. Finally, Robert W. Baird reiterated a “buy” rating and issued a $95.00 target price (up previously from $82.00) on shares of Davita in a research report on Friday, January 12th.

How to Become a New Pot Stock Millionaire

Institutional investors have recently added to or reduced their stakes in the business. Captrust Financial Advisors purchased a new stake in Davita in the 4th quarter worth approximately $113,000. Country Club Trust Company n.a. purchased a new stake in Davita in the 4th quarter worth approximately $207,000. Green Square Capital LLC purchased a new stake in Davita in the 4th quarter worth approximately $217,000. Kovitz Investment Group Partners LLC purchased a new stake in Davita in the 4th quarter worth approximately $221,000. Finally, Berkshire Asset Management LLC PA purchased a new stake in Davita in the 4th quarter worth approximately $234,000. Institutional investors and hedge funds own 85.79% of the company’s stock.

Shares of DVA traded down $0.09 during mid-day trading on Thursday, hitting $63.08. 1,315,364 shares of the company traded hands, compared to its average volume of 1,564,193. Davita has a 1-year low of $52.51 and a 1-year high of $80.71. The company has a quick ratio of 2.82, a current ratio of 2.88 and a debt-to-equity ratio of 1.87. The company has a market cap of $11,447.80, a P/E ratio of 19.00, a price-to-earnings-growth ratio of 0.90 and a beta of 1.09.

Davita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, February 13th. The company reported $0.92 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.94 by ($0.02). The company had revenue of $2.78 billion for the quarter, compared to analyst estimates of $3.90 billion. Davita had a net margin of 4.65% and a return on equity of 12.86%. During the same quarter last year, the company earned $0.98 EPS. research analysts anticipate that Davita will post 4.15 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://ledgergazette.com/2018/04/17/davita-inc-dva-receives-79-00-average-price-target-from-brokerages.html.

About Davita

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Analyst Recommendations for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply